Vaccines - Republic of the Congo

Republic of the Congo

The Vaccines market in the Republic of the Congo is anticipated to achieve a revenue of US$10.71m in 2024.
This market is expected to display a compound annual growth rate (CAGR 2024-2029) of -12.57%, leading to a market volume of US$5.47m by 2029.
When compared globally, United States is projected to generate the highest revenue, amounting to US$29,120.00m in 2024.
The Republic of the Congo has seen a significant increase in demand for vaccines, driven by the government's efforts to improve healthcare infrastructure and prevent the spread of infectious diseases.

Key regions: Australia, Italy, France, South Korea, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The Republic of the Congo, a country located in Central Africa, has seen a steady development in the Vaccines market in recent years.

Customer preferences: One of the main customer preferences in the Republic of the Congo is for vaccines that provide protection against diseases such as measles, polio, and yellow fever. This is due to the prevalence of these diseases in the country. Additionally, there is a growing demand for vaccines that provide protection against COVID-19.

Trends in the market: The Vaccines market in the Republic of the Congo has seen a trend towards increased government investment in healthcare infrastructure, which has led to an increase in the availability of vaccines across the country. There has also been a trend towards the adoption of new vaccine technologies, such as mRNA vaccines, which has led to an increase in the variety of vaccines available in the market.

Local special circumstances: One of the main local special circumstances in the Republic of the Congo is the prevalence of infectious diseases such as malaria, tuberculosis, and HIV/AIDS. This has led to a greater demand for vaccines that provide protection against these diseases. Additionally, the country has a large rural population, which can make it difficult to distribute vaccines to all parts of the country.

Underlying macroeconomic factors: The Republic of the Congo has a relatively small economy, which has limited the amount of investment in the healthcare sector. However, the government has made efforts to increase investment in healthcare infrastructure in recent years, which has led to an increase in the availability of vaccines. Additionally, the country has a young population, which has led to a greater demand for vaccines that provide protection against childhood diseases.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.